Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is conducting a Phase 2 study titled A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma. The study aims to assess the effectiveness of linvoseltamab in eliminating abnormal plasma cells in patients at moderate risk of developing multiple myeloma, focusing on those with precancerous conditions like HR-MGUS and NHR-SMM.
The intervention being tested is linvoseltamab, an investigational drug designed to target and eliminate abnormal plasma cells that could progress to multiple myeloma. The study seeks to determine its efficacy and safety in this context.
The study is interventional with a non-randomized, sequential model and no masking. It primarily aims to treat the conditions in question. The study consists of a safety run-in phase followed by an expansion phase with multiple dosing regimens.
The study began on October 31, 2023, with an estimated completion date of August 26, 2025. These dates are crucial for tracking the study’s progress and anticipating potential results.
This clinical update could influence Regeneron’s stock performance and investor sentiment, especially if linvoseltamab proves effective. Given the competitive landscape in cancer treatment, successful outcomes could position Regeneron favorably against its peers.
The study is ongoing, with further details available on the ClinicalTrials portal.